Yahoo Finance • last year
Nurix Therapeutics, Inc. Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily pretreated relapsed/... Full story
Yahoo Finance • last year
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Nurix Therapeutics, Inc. (NASDAQ: NRIX) (“Nurix”) on behalf of the company’s investors. Since July 2023, shares of Nurix’s common stock h... Full story
Yahoo Finance • last year
SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story
Yahoo Finance • last year
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story
Yahoo Finance • last year
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story
Yahoo Finance • last year
Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Achieved an additional $8 million in research milestones for the quarter, resulting in milest... Full story
Yahoo Finance • last year
In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Ca... Full story
Yahoo Finance • last year
Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Received $20 million licensing payment fro... Full story
Yahoo Finance • 2 years ago
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuselarge B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated in patients with mantle cell lymphoma (... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and... Full story
Yahoo Finance • 2 years ago
Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights specificity and potency of NX-5948 and superio... Full story
Yahoo Finance • 2 years ago
Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthri... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies a... Full story
Yahoo Finance • 2 years ago
https://cdn.benzinga.com/files/images/story/2023/03/20/gild.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational... Full story
Yahoo Finance • 2 years ago
MARKET PULSE Shares of Nurix Therapeutics Inc. (NRIX) gained about 6% in premarket trading on Monday after Gilead Sciences Inc. (GILD) said it exercised the option to exclusively license Nurix’s targeted protein degrader molecule, which is... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies a... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies a... Full story
Yahoo Finance • 2 years ago
Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and partnered preclinical progra... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story
Yahoo Finance • 2 years ago
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resistance to both c... Full story